Diligence memo · auto-generated · as of July 2, 2026
Novalar Pharmaceuticals Inc
Novalar Pharmaceuticals Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Novalar Pharmaceuticals Inc operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Novalar Pharmaceuticals Inc has raised $1.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.0M on 2010-07-16.
Most recent recorded round closed around 2010-07-16.
Valuation (modeled)modeled
Provath models Novalar Pharmaceuticals Inc at approximately $44M (range $721K–$349M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 16.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).
Modeled value ranks above 43% of those peers.
Closest niche peers: Denali Medical II, Inc., Signum Biosciences, Inc., Health Elements, LLC, Nkt Therapeutics Inc, Surface Logix Inc.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.